Skip to main content

Table 4 PFS (progression free survival) according to  KRAS  mutation for the two different treatment arms

From: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

PFS

FUFOX

CAPOX

p-value (log rank)

 

n = 105

n = 96

HR (95% CI)

All patients

8.2 months

6.4 months

0.18

0.81 (0.61-1.09)

WT

8.1months

6.4months

0.29

   

0.82 (0.56-1.19)

Codon 12 mutation

9.9months

7.0months

0.12

   

0.62 (0.33-1.14)

Codon 13 mutation

6.1months

13.3months

0.22

   

2.52 (0.54-11.70)

  1. PFS, HR hazard ratio by cox regression, CI confidence interval, WT wild type.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us